Ferring licenses Ligand's OmniAb antibodies platform

Jan 2018

Ligand Pharmaceuticals Inc. licensed worldwide rights to its OmniAb antibody platform to Ferring Pharmaceuticals.

Biotechnology
- Drug Discovery Tools
- Large Molecule
  - Antibodies
- Transgenics
Pharmaceuticals

Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing

Already a Strategic Transactions subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

Related Companies

Ferring licenses Ligand's OmniAb antibodies platform

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice